COPD管理云平台的构建及临床应用

doi:10.3877/cma.j.issn.1674-6902.2023.04.006

目的

构建慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)远程智能管理微信小程序云平台，实现对COPD稳定期患者日常规范化管理。

方法

构建基于微信小程序的远程智能管理云平台；选择2020年12月至2022年12月我院收治的COPD患者106例，将云平台管理53例为观察组，常规管理53例为对照组。对比两组1年内治疗依从性、肺功能变化、症状评分、急性加重次数、住院次数、住院费用和住院天数差异，评估平台应用效能。

结果

成功构建COPD远程智能管理微信小程序；观察组较对照组规范用药比例(64.2% vs. 43.4%)高、急性加重次数[(1.04±0.83)次vs.(1.51±0.89)次]少、住院次数[(0.66±0.71)次vs.(1.13±0.86)次]少、住院费用[(0.41±0.41)万元vs.(0.63±0.40)万元]和住院天数[(4.92±4.96)d vs.(7.40±4.95)d]少(P<0.05)。两组肺功能、症状评分无显著差异(P>0.05)。

结论

构建COPD远程智能管理云平台，提高COPD稳定期患者远程自我管理效能，提升生活质量，是"互联网+慢病管理"创新医疗服务模式的有益探索。

关键词: 肺疾病，慢性阻塞性, 微信小程序, COPD远程智能管理, 治疗依从性

Objective

To build a remote intelligent management WeChat mini program cloud platform for COPD, to achieve standardized daily management of COPD stable phase patients.

Methods

It was built that a remote intelligent management cloud platform based on wechat mini program; It was selected that 106 patients with COPD treated in our hospital from December 2020 to December 2022, 53 cases were treated as observation group by cloud platform management, and 53 cases were treated as control group by routine management. Treatment compliance, pulmonary function changes, symptom scores, acute aggravation times, hospitalization times, hospitalization costs and hospitalization days were compared between the two groups within 1 year to evaluate the application effectiveness of the platform.

Results

The wechat mini program of remote intelligent management of COPD was successfully built; The proportion of standard drug use in observation group was higher than that in control group (64.2% vs. 43.4%), the number of acute exacerbations [(1.04±0.83) vs. (1.51±0.89)] less, the number of hospitalizations [(0.66±0.71) vs. (1.13±0.86)] less, the hospitalization cost [(0.41±0.41) yuan vs. (0.63±0.40) yuan] and the length of hospitalization [(4.92±4.96) d vs. (7.40±4.95)d] less, P<0.05. There were no significant differences in pulmonary function and symptom scores between the two groups (P>0.05).

Conclusion

The construction of a remote intelligent management Cloud platform for COPD is beneficial in improving the remote self-management efficacy of COPD stable phase patients, enhancing their quality of life, and is a beneficial exploration of the innovative medical service model of "Internet + chronic disease management" .

Key words: Chronic obstructive pulmonary disease, WeChat app, Remote intelligent management of COPD, Treatment compliance

表1 两组临床基线资料比较

临床资料	观察组(n＝53)	对照组(n＝53)	t(χ²)	P值
年龄(岁)	69.9±9.2	68.9±7.8	0.625	0.533
性别(男/女)	43/10	38/15	1.309	0.253
BMI	22.4±2.5	21.8±2.0	1.334	0.185
吸烟[n(%)]	12(22.60)	11(20.80)	0.056	0.814
饮酒[n(%)]	13(24.50)	6(11.30)	3.142	0.076
肺源性心病[n(%)]	10(18.90)	14(26.40)	0.862	0.353
糖尿病[n(%)]	13(24.50)	9(17.00)	0.918	0.338
FEV₁%pre	49.9±14.5	50.4±15.7	－0.185	0.853
CAT评分	16.3±3.0	1.60±3.2	0.5	0.618
mMRC评分	1.94±0.53	1.92±0.61	0.169	0.866
家庭氧疗[n(%)]	8(15.10)	12(22.60)	0.986	0.321
用药是否规律[n(%)]	18(34.00)	16(30.20)	0.173	0.677
前一年急性加重次数	2.00±0.96	2.02±0.98	－0.11	0.913
前一年住院次数	1.57±0.97	1.72±0.84	－0.856	－0.394

表1 两组临床基线资料比较

临床资料	观察组(n＝53)	对照组(n＝53)	t(χ²)	P值
年龄(岁)	69.9±9.2	68.9±7.8	0.625	0.533
性别(男/女)	43/10	38/15	1.309	0.253
BMI	22.4±2.5	21.8±2.0	1.334	0.185
吸烟[n(%)]	12(22.60)	11(20.80)	0.056	0.814
饮酒[n(%)]	13(24.50)	6(11.30)	3.142	0.076
肺源性心病[n(%)]	10(18.90)	14(26.40)	0.862	0.353
糖尿病[n(%)]	13(24.50)	9(17.00)	0.918	0.338
FEV₁%pre	49.9±14.5	50.4±15.7	－0.185	0.853
CAT评分	16.3±3.0	1.60±3.2	0.5	0.618
mMRC评分	1.94±0.53	1.92±0.61	0.169	0.866
家庭氧疗[n(%)]	8(15.10)	12(22.60)	0.986	0.321
用药是否规律[n(%)]	18(34.00)	16(30.20)	0.173	0.677
前一年急性加重次数	2.00±0.96	2.02±0.98	－0.11	0.913
前一年住院次数	1.57±0.97	1.72±0.84	－0.856	－0.394

表2 6个月后两组管理效果比较[±s，(%)]

临床资料	观察组(n＝53)	对照组(n＝53)	t(χ²)	P值
FEV₁%pre	56.16±13.05	53.43±13.06	1.075	0.285
CAT评分	13.57±2.19	13.75±2.64	－0.401	0.689
mMRC评分	1.72±0.53	1.83±0.67	－0.961	0.339
家庭氧疗[n(%)]	11(20.80)	13(24.50)	0.215	0.643
用药是否规律[n(%)]	34(64.20)	23(43.40)	4.592	0.032
前一年急性加重次	1.04±0.83	1.51±0.89	－2.819	0.006
前一年住院次数	0.66±0.71	1.13±0.86	－3.096	0.003
住院费用	0.41±0.41	0.63±0.40	－2.762	0.007
住院天数	4.92±4.96	7.40±4.95	－2.57	0.012

表2 6个月后两组管理效果比较[±s，(%)]

临床资料	观察组(n＝53)	对照组(n＝53)	t(χ²)	P值
FEV₁%pre	56.16±13.05	53.43±13.06	1.075	0.285
CAT评分	13.57±2.19	13.75±2.64	－0.401	0.689
mMRC评分	1.72±0.53	1.83±0.67	－0.961	0.339
家庭氧疗[n(%)]	11(20.80)	13(24.50)	0.215	0.643
用药是否规律[n(%)]	34(64.20)	23(43.40)	4.592	0.032
前一年急性加重次	1.04±0.83	1.51±0.89	－2.819	0.006
前一年住院次数	0.66±0.71	1.13±0.86	－3.096	0.003
住院费用	0.41±0.41	0.63±0.40	－2.762	0.007
住院天数	4.92±4.96	7.40±4.95	－2.57	0.012

3	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
4	Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis[J]. Lancet Respir Med, 2022, 10(5): 447-458.
5	国务院办公厅发布《关于促进"互联网+医疗健康"发展的意见》[J]. 医学信息学杂志，2018, 39(5): 94-95.
6	Luan H, Wang M, Sokol RL, et al. A scoping review of WeChat to facilitate professional healthcare education in Mainland China[J]. Med Educ Online, 2020, 25(1): 1782594.
7	蔡莎莎，王雅楠. 高校微信平台"开学季"传播策略的实证研究——基于福建省5所本科高校微信公众平台的分析[J]. 厦门理工学院学报，2019, 27(4): 21-27.
8	Wu Q, Huang Y, Liao Z, et al. Effectiveness of WeChat for Improving Exclusive Breastfeeding in Huzhu County China: Randomized Controlled Trial[J]. J Med Internet Res, 2020, 22(12): e23273.
9	周芯宇，陈　伟，吴国全，等. REST API设计分析及实证研究[J]. 软件学报，2022, 33(9): 3271-3296.
10	Poniszewska-Maranda A, Czechowska E. Kubernetes Cluster for Automating Software Production Environment[J]. Sensors (Basel), 2021, 21(5): 1910.
11	Campbell WS, Pedersen J, McClay JC, et al. An alternative database approach for management of SNOMED CT and improved patient data queries[J]. J Biomed Inform, 2015, 57: 350-357.
12	Omboni S, Campolo L, Panzeri E. Telehealth in chronic disease management and the role of the Internet-of-Medical-Things: the Tholomeus(R) experience[J]. Expert Rev Med Devices, 2020, 17(7): 659-670.
13	Wang Y, Yin A, Bian T, et al. Observation of efficacy of internet-based chronic disease management model combined with modified therapy of bushenyiliu decoction in treating patients with type 2 diabetes mellitus and prostate cancer and its effect on disease control rate[J]. Evid Based Complement Alternat Med, 2021, 2021: 7767186.
14	Hanlon P, Daines L, Campbell C, et al. Telehealth interventions to support self-management of long-term conditions: A systematic metareview of diabetes, heart failure, asthma, chronic obstructive pulmonary disease, and cancer[J]. J Med Internet Res, 2017, 19(5): e172.
15	Rassouli F, Boutellier D, Duss J, et al. Digitalizing multidisciplinary pulmonary rehabilitation in COPD with a smartphone application: an international observational pilot study[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3831-3836.
16	Moore E, Chatzidiakou L, Jones RL, et al. Linking e-health records，patient-reported symptoms and environmental exposure data to characterise and model COPD exacerbations: protocol for the COPE study[J]. BMJ Open, 2016, 6(7): e11330.
17	GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional，and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med, 2017, 5(9): 691-706.
18	Zoeckler N, Kenn K, Kuehl K, et al. Illness perceptions predict exercise capacity and psychological well-being after pulmonary rehabilitation in COPD patients[J]. J Psychosom Res, 2014, 76(2): 146-151.
19	Rivera E, Corte C, Steffen A, et al. Illness representation and self-care ability in older adults with chronic disease[J]. Geriatrics (Basel), 2018, 3(3): 45.
1	梁振宇，王凤燕，陈子正，等. 2023年GOLD慢性阻塞性肺疾病诊断、管理及预防全球策略更新要点解读[J]. 中国全科医学，2023, 26(11): 1287-1298.
2	任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
20	Lopes AC, Xavier RF, Ac PA, et al. Identifying COPD patients at risk for worse symptoms, HRQoL, and self-efficacy: A cluster analysis[J]. Chronic Illn, 2019, 15(2): 138-148.
21	Jensen MH, Cichosz SL, Dinesen B, et al. Moving prediction of exacerbation in chronic obstructive pulmonary disease for patients in telecare[J]. J Telemed Telecare, 2012, 18(2): 99-103.
22	Kronborg T, Mark L, Cichosz SL, et al. Population exacerbation incidence contains predictive information of acute exacerbations in patients with chronic obstructive pulmonary disease in telecare[J]. Int J Med Inform, 2018，111: 72-76.
23	Chang Y, Xu L, Han F, et al. Validation of the Nox-T3 portable monitor for diagnosis of obstructive sleep apnea in patients with chronic obstructive pulmonary disease[J]. J Clin Sleep Med, 2019, 15(4): 587-596.
24	Janjua S, Carter D, Threapleton CJ, et al. Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD)[J]. Cochrane Database Syst Rev, 2021, 7(7): D13196.
25	Cruz J, Brooks D, Marques A. Home telemonitoring in COPD: a systematic review of methodologies and patients′adherence[J]. Int J Med Inform, 2014, 83(4): 249-263.
26	Donner CF, ZuWallack R, Nici L. The role of telemedicine in extending and enhancing medical management of the patient with chronic obstructive pulmonary disease[J]. Medicina (Kaunas), 2021, 57(7): 726.
27	Buekers J, Theunis J, De Boever P, et al. Wearable finger pulse oximetry for continuous oxygen saturation measurements during daily Home routines of patients with chronic obstructive pulmonary disease (COPD) over one week: Observational study[J]. JMIR Mhealth Uhealth, 2019, 7(6): e12866.
28	Hawthorne G, Greening N, Esliger D, et al. Usability of wearable multiparameter technology to continuously monitor free-living vital signs in people living with chronic obstructive pulmonary disease: Prospective observational study[J]. JMIR Hum Factors, 2022, 9(1): e30091.
29	Hawthorne G, Richardson M, Greening NJ, et al. A proof of concept for continuous, non-invasive, free-living vital signs monitoring to predict readmission following an acute exacerbation of COPD: a prospective cohort study[J]. Respir Res, 2022, 23(1): 102.

[1]	马锦芳, 何正光, 郑劲平. 盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病黏痰症患者的疗效和安全性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 568-574.
[2]	程炜炜, 张青, 张诚实, 冯契靓, 陈荣荣, 赵云峰. 全身免疫炎症指数与慢性阻塞性肺疾病急性加重期病情严重程度相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 580-584.
[3]	杨万荣, 任治坤, 时新颍. 沙丁胺醇雾化吸入脾多肽治疗AECOPD的疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 609-612.
[4]	赖乾德, 吕相琴, 蔺洋, 刘媛梅, 赵春艳, 李琦. 肝素结合蛋白对慢性阻塞性肺疾病预后预测分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 613-616.
[5]	王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[6]	方晓玉, 王婷, 赵珊, 陈锋. HALP指数对AECOPD并发呼吸衰竭患者ICU结局的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 639-641.
[7]	郭少琳, 郭建英, 左秀萍, 高苗. 慢性阻塞性肺疾病康复训练依从性影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 652-654.
[8]	白若靖, 郭军. 维生素D对肺部疾病临床意义的研究进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 659-662.
[9]	孔令梅, 徐晓媛, 马丽颖. 慢性阻塞性肺疾病认知衰弱危险因素及预后分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 407-410.
[10]	徐艳, 江秀娟, 王超, 江圆满. 股直肌剪切波弹性成像对COPD并发肌少症的诊断意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 454-457.
[11]	黄映兰, 骆丽萍, 郭慧玲, 袁麟标. 慢性阻塞性肺疾病糖皮质激素治疗反应性的影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 469-471.
[12]	杨坤, 赵景成, 吴永强. 无创呼吸机在慢性阻塞性肺疾病并发呼吸衰竭救治的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 481-483.
[13]	宋素莉, 贺英华, 陈丽娟. COPD并发吸入性CAP危险因素及病原菌分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 264-267.
[14]	陈婷婷, 李春娟. 经鼻高流量湿化氧疗治疗AECOPD伴Ⅱ型呼吸衰竭的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 276-279.
[15]	周文欢, 杨黎. AECOPD低钠血症发生风险及预测因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 313-315.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Construction and clinical application of chronic obstructive pulmonary disease management cloud platform

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Construction and clinical application of chronic obstructive pulmonary disease management cloud platform